Program Description
In collaboration with the National Association of Specialty Pharmacy.
Generalized myasthenia gravis (gMG) is a chronic, immune-mediated disorder of the neuromuscular junction that causes fluctuating muscle weakness and fatigue across ocular, bulbar, limb, and respiratory muscle groups, often limiting patients’ daily functioning and quality of life. Variability in antibody profiles and disease severity adds specific challenges to gMG management. Even with foundational therapies, many patients continue to experience incomplete symptom control or unpredictable exacerbations. A deeper understanding of the immunologic drivers of gMG has since contributed to the development of targeted biologics, including FcRn blockers and complement inhibitors, that interrupt key disease pathways. As these potentially more individualized treatment strategies reshape the standard of care, specialty pharmacists will be increasingly involved in decisions to guide therapy selection, anticipate safety concerns, and support the monitoring and counseling patients need throughout treatment. This webinar provides specialty pharmacists with a comprehensive overview of gMG pathophysiology and standards of care. The mechanisms and clinical data behind the evolving treatment landscape will be presented, with key insights to help pharmacists translate this knowledge into practical guidance that supports multidisciplinary collaboration and treatment monitoring for patients with gMG.
Target audience: Specialty pharmacists
Type of activity: Application
Release date: October 8, 2026
Expiration date: December 8, 2026
Time to complete activity: 1 hour
Learner level: Foundational, Intermediate
Fee: Free
Educational Objectives
At the completion of this activity, participants will be able to:
- Identify the pathophysiology, clinical manifestations, and current management approaches for generalized myasthenia gravis (gMG), including standards of care and therapeutic gaps
- Explain the mechanisms of action of approved and emerging targeted therapies for gMG and their place in the evolving treatment landscape
- Provide multidisciplinary care for patients with gMG, considering common adverse events, key monitoring needs, and clear patient education about therapy use and expectations
Erica Marini, PharmD, MS, BCPS
Clinical Pharmacist, Neurology
University of Utah Health
Salt Lake City, UT
Accreditation Information
Pharmacy Times Continuing Education™ is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education. This activity is approved for 1.0 contact hour (0.10 CEU) under the ACPE universal activity number 0290-0000-26-277-L01-P. The activity is available for CE credit through December 8, 2026.
Instructions for Completing the Activity and Receiving CPE Credit
To
receive CPE credit, participants must complete the pretest, review the activity in
its entirety, complete the posttest, and complete the online activity
evaluation. After successful completion of the online activity evaluation, you
can submit your credit to CPE Monitor. You may view your credit within 48 hours
at www.mycpemonitor.net. All participants must request credit before the
activity expiration date. CE credit will not be issued after this date.
Disclosures
Erica Marini, PharmD, MS, BCPS, has no relevant financial relationships with ineligible companies to disclose.
Pharmacy Times Continuing Education™ Planning Staff: Jim Palatine, RPh, MBA; Dipti Desai, PharmD, MBA, CHCP; Kylie Ferrentino; and Brianna Winters; have no financial relationships with ineligible companies to disclose.
All of the relevant financial relationships listed for these individuals have been mitigated.
At least one anonymous peer reviewer has been used as part of content validation and conflict resolution. The peer reviewer has no relevant financial relationships with ineligible companies to disclose.
Educational Disclaimer
CPE activities are offered solely for educational purposes and do not constitute any form of professional advice or referral. Discussions concerning drugs, dosages, and procedures may reflect the clinical experience of the author(s) or they may be derived from the professional literature or other sources and may suggest uses that are investigational in nature and not approved labeling or indications. Participants are encouraged to refer to primary references or full prescribing information resources.
For questions about this internet CPE activity, please contact:
[email protected]
Privacy Policy and Terms of Use Information:
www.pharmacytimes.org/terms